are successfully strong Thank a our approval the including excellent another quarter biosimilar across driven of diversified execution This achieved customer integrate, the service scientific performance our pipeline, Glargine. was you, of everyone. We with we while to to commercial interchangeable and very navigate strong continued an good levels, COVID-XX entire Insulin first continue pleased business had pandemic. restructure historic by morning, and momentum positive supported and Michael, by
global Our continued I performance commitment. would for dedication would them their to of not like the be possible our and without thank workforce,
certain constant comparisons as next LOE guidance. a two adjusted were XXXX X, of excluding the XXXX the Slide several and the Lyrica compared slides, results. bottom and product included X% When up adjusted I this the the of second each combined net on as slide, a versus our will the quarter on making as seen each categories. LOEs, product as performance. sales performance LOE combined Japan's expectations Celebrex of Over be well through of initial segments to in quarter on our comparisons categories as in you basis, will currency the our our to Beginning quarter delivered side impact strong results and I segments walk left-hand
year-over-year expectations. X% XX% by generics grew category and performed business by while biosimilar grew our portfolio brand to global report competition our certain better to pleased and year-over-year that biosimilar in complex quarter, our Our overall our X% mainly anticipated complex than due We're by declined generics portfolio. on products this
on delivered Our XXXX. We performed in of geography. new diversity our impact global we generic our better perform than product to and and year-over-year reach, our or business $XXX base meet as ahead, strongly. the reliance X% second $XXX expectations. by on well million in expect commercial our we the Accordingly, quarter to changes to to as for grew track target look we We any and believe business in remain portfolio any the of our the that positions market million continue balance and launches eliminates one
by X, year-over-year. like Slide Developed to Yupelri, by and This was grew primarily brands Market driven X% Creon. segment Turning our Dymista
to expand Our and continues grow which Thrombosis performed than our the better and established our highlight expected, to hospital also manage segment. brands effectively presence ability in portfolio
biosimilars which XX% growth competition the Xulane. Our helped to anticipated the performed impact Wixela negative strongly this offset previously of and quarter, with
expectations, also continued competition our portfolio anticipated our biosimilars portfolio driven growth generic favorable our by generics complex Europe. Our that, offsetting in portfolio we Having U.S. said injectables as than as primarily while driving performed patterns well in COVID-related buying space. better our see
next to Slide. the Moving
and performed certain countries as Brands growth and Our strong than performance like segment COVID. our expectations. delivered recovering drove Lyrica from Emerging better Market year-over-year started XX% Viagra
slide better expectations. our year-over-year of Our JANZ generic next segment line grew by that X% certain with shows The than performed our results in was business and helped COVID expected our products. related
products of EpiPen, and performance primarily to strong of Japan. like brand Our the contributed portfolio Lyrica
slide our expanded to continue growth with which year. growth, the JANZ. expectations. should offering our and of including collaboration Lyrica our is the pleased half and that The our from termination overall shows China our Pfizer We performance business business next again Especially, Celebrex. be our in from is a generics of once generics strong due was better It the to noted generics delivered to of be that prior last the than contribution with the authorized approximately segment slide generics Greater authorized
and decline VBP was Our impact implementation retail channel while than of channel showed and and URP. our our performed VBP X% double-digit year-over-year growth expectations, managing better driven Celebrex hospital of The by Zoloft. anticipated the
year we the original at of than look full anticipate better the to As our the expectations. year, rest we be
Although, second see the being implementation the of we first than half URP. softer the of because
policy approval years confidence turning several down best-in-class to diligently We our from our barriers the to work capabilities requires deep recently, to to pathways our to will R&D, key on highly complex approval pipeline. and nine collaboratively and clear XX. line Neulasta, that patients. Slide first-to-market to of you Copaxone to The regulators, record experts to development molecules. Slide are intend and and pipeline walk cross through XX, to an the goes leverage on that track access. the on Advair, functional Getting which stakeholders hurdles Now tremendous signs team take average nature access these now some our XX well-positioned to expand interchangeable scientific introducing proven the perseverance, the further can enables create starting beyond of for give our and Lantus, Herceptin, first complex regulatory, partners products unwavement to for updates Breaking great highlights day and with biosimilar from of complex I regulatory products. seven most medical right of given legal, one, to we It first deliver other and us success Symbicort patients. the an tenacity stories receiving milligram finished seek
of moment opportunity to remarks As this launch many a before who first approval year. We key Viatris exciting would our the to so biosimilars Semglee. and to end in I echo achieving applaud played to pipeline, a historic forward the Michael's biosimilar interchangeable take FDA the it efforts relates role of look colleagues, like the of this huge
a four to of Biocon track We end for interchangeable for remain is scheduled for FDA, on we expand submission a of on Fbat Fbat, manufacturing we for Scientifically, this in in pre-approval achieve Moving Malaysia Eylea. which to the quarter. now inspection schedule insulin. year a facility our believe should from further interchangeability of are portfolio quarter this
have for Botox path FDA a to progressing is forward. in with program and this meeting scheduled September the we Our well year of our align on
to biosimilar Moving to Avastin.
with impacted no same While COVID restrictions. to regulators. MHRA we our U.S. scientific product has has inspection due by pre-approval questions other delay been travel several approval approved have the open by EEA, a and FDA, been The in
planned. to As complex steady June milestones. and you Solution slide, will XXXbX we on make have important see continue our upcoming submitted application in the our to as Oral some on product our progress FDA Levothyroxine next program for We
an of IND initiate quarter new expect We're for Xulane program dosing Phase year. with and our plan excited our September. progress four this in formulation planned with Meloxicam, we for submission study of For the clinical we X to our low-dose Phase Xb our
We progress also to injectables pipeline. complex continue our on make comprehensive
XXX XXX We milligram acceptance from submitted XXX are XXX Invega on and Trinza that three-month first been we report of and milligram have on remaining are to and to product, are The the trend trend. happy to equivalent milligram pending already Paliperidone file FDA. once
of structuring teams to I hard the Since Before no upon almost touch transaction at integration like at confident $X this least have closing on plans and year synergies track been work I and billion cost in realize ensure business XXXX. nine our by $XXX would months achieve overall remain conclude, ago, our to synergies disruption. deep to of cost activities. our million to We
Let call to Sanjeev. turn over me you. Thank the now
